

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1D01
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733

In re Application of THOMSON	
Application Number 08/376327	Filed 1/20/95
Paper No. 32	

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. **5843780** page, _____ line _____

United States Patent Number _____, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____


Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.



Signature

ERIC WHITE

Typed or printed name

Registration Number, if applicable

Telephone Number

5/8/06

Date	5/8/06
RECEIVED	
FOR MAY 8 2006	
Approved by	File Information Unit
(Initials)	
Unit	



US 5,843,780A

United States Patent [19]**Thomson**[11] **Patent Number:** **5,843,780**[45] **Date of Patent:** **Dec. 1, 1998**[54] **PRIMATE EMBRYONIC STEM CELLS**[75] **Inventor:** **James A. Thomson, Madison, Wis.**[73] **Assignee:** **Wisconsin Alumni Research Foundation, Madison, Wis.**[21] **Appl. No.:** **591,246**[22] **Filed:** **Jan. 18, 1996****Related U.S. Application Data**[63] **Continuation-in-part of Ser. No. 376,327, Jan. 20, 1995.**[51] **Int. Cl.⁶** **C12N 5/06**[52] **U.S. Cl.** **435/363; 435/366; 435/373**[58] **Field of Search** **435/363, 366, 435/373**[56] **References Cited****U.S. PATENT DOCUMENTS**

5,449,620 9/1995 Khillan .
 5,453,357 9/1995 Hogan 435/7.21
 5,591,625 1/1997 Gerson et al. .

FOREIGN PATENT DOCUMENTS

WO 94/03585 2/1994 WIPO .

OTHER PUBLICATIONS

Bongso, et al., "Isolation and culture of inner cell mass cells from human blastocysts", *Human Reproduction*, 9:2110-2117, 1994.

Brown, et al., "Criteria that optimize the potential of murine embryonic stem cells for in vitro and in vivo developmental studies", *In Vitro Cell. Dev. Biol.* 284:773-778, Dec. 1992.

Damjanov, et al., "Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT", *Laboratory Investigation*, 68:220-232, 1993.

Nation/World, "Embryonic monkey cells isolated". -Nov. 4, 1994.

Bongso, A., et al., "The Growth of Inner Cell Mass Cells from Human Blastocysts," *Theriogenology*, 41:167 (1994).

Thomson, James A., et al., "Pluripotent Cell Lines Derived from Common Marmoset (*Callithrix jacchus*) Blastocysts," *Biology of Reproduction*, 55:254-259 (1996).

Primary Examiner—Michael P. Woodward**Assistant Examiner**—Brenda G. Brumback**Attorney, Agent, or Firm**—Quarles & Brady[57] **ABSTRACT**

A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (-); SSEA-3 (+); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation have normal karyotypes and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.

11 Claims, 8 Drawing Sheets